文献速递临床微生物分子诊断临床免疫

单分子计数技术超灵敏检测粪便中艰难梭菌毒素与细胞培养细胞毒性中和试验的比较

Ultrasensitive Detection of Clostridioides difficile Toxins in Stool by Use of Single-Molecule Counting Technology: Comparison with Detection of Free Toxin by Cell Culture Cytotoxicity Neutralization Assay.
PubMed 文献 · J Clin Microbiol · 2019-10-23

该研究通过两项前瞻性多中心研究比较Singulex Clarity艰难梭菌毒素A/B检测与细胞培养细胞毒性中和试验(CCCNA),设定Clarity cut-off为12.0 pg/ml;验证中经 discrepant 样本复测后阳性一致率96.3%、阴性一致率93.0%,毒素EIA阳性一致率59.8%。

要点

  • Clarity检测cut-off为12.0 pg/ml,与CCCNA阳性一致率96.3%、阴性一致率93.0%。
  • 复测差异样本后CCCNA结果变化达42%,提示CCCNA参考标准存在挑战。
  • Clarity是最灵敏的游离毒素免疫检测,可一步诊断CDI。

核心结论

  • Clarity检测与CCCNA比较,复测差异样本后阳性一致率96.3%,阴性一致率93.0%。
  • Clarity是最灵敏的游离毒素免疫检测,可提供单步CDI诊断。
  • 42%的复测样本CCCNA结果不同,提示以CCCNA为参考标准比较游离毒素结果存在挑战。

研究设计与样本

  • 两项前瞻性多中心研究:设定cut-off阶段2个中心检测897例疑似CDI受试者新鲜样本;验证阶段4个中心检测1,005例疑似CDI受试者新鲜样本。
  • CCCNA在中心实验室进行;Clarity与CCCNA结果不一致且Clarity与至少一种比较方法一致时复测CCCNA。
  • 所有样本均进行毒素酶免疫分析(EIA)、谷氨酸脱氢酶(GDH)检测和PCR。

主要发现

  • Clarity检测cut-off设定为12.0 pg/ml。
  • 与CCCNA比较,Clarity初始阳性一致率85.2%,阴性一致率92.4%。
  • 验证研究中复测差异样本后,13/17(76.5%)Clarity阴性但CCCNA阳性样本转为CCCNA阴性,5/26(19.2%)Clarity阳性但CCCNA阴性样本转为CCCNA阳性。
  • 复测后Clarity与CCCNA阳性一致率96.3%,阴性一致率93.0%。
  • 毒素EIA与CCCNA阳性一致率59.8%。

关键数值与推荐

  • Clarity检测cut-off为12.0 pg/ml。
  • 复测后Clarity与CCCNA阳性一致率96.3%,阴性一致率93.0%。
  • 毒素EIA与CCCNA阳性一致率59.8%。

临床怎么用

  • Clarity检测可作为单步解决方案用于CDI诊断。
  • Clarity是最灵敏的游离毒素免疫检测。
  • 以CCCNA为参考标准比较游离毒素结果时需注意复测可能改变结果。

局限性

  • 42%的复测样本CCCNA结果不同,提示CCCNA作为参考标准存在挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Laboratory tests for Clostridioides difficile infection (CDI) rely on the detection of free toxin or molecular detection of toxin genes. The Singulex Clarity C. diff toxins A/B assay is a rapid, automated, and ultrasensitive assay that detects C. difficile toxins A and B in stool. We compared CDI assays across two prospective multicenter studies to set a cutoff for the Clarity assay and to independently validate the performance compared with that of a cell culture cytotoxicity neutralization assay (CCCNA). The cutoff was set by two sites testing fresh samples from 897 subjects with suspected CDI and then validated at four sites testing fresh samples from 1,005 subjects with suspected CDI. CCCNA testing was performed at a centralized laboratory. Samples with discrepant results between the Clarity assay and CCCNA were retested with CCCNA when the Clarity result agreed with that of at least one comparator method; toxin enzyme immunoassays (EIA), glutamate dehydrogenase (GDH) detection, and PCR were performed on all samples. The cutoff for the Clarity assay was set at 12.0 pg/ml. Compared to results with CCCNA, the Clarity assay initially had 85.2% positive agreement and 92.4% negative agreement. However, when samples with discrepant results between the Clarity assay and CCCNA in the validation study were retested by CCCNA, 13/17 (76.5%) Clarity-negative but CCCNA-positive samples (Clarity+/CCCNA-) became CCCNA-, and 5/26 (19.2%) Clarity+/CCCNA- samples became CCCNA+, resulting in a 96.3% positive agreement and 93.0% negative agreement between Clarity and CCCNA results. The toxin EIA had 59.8% positive agreement with CCCNA. The Clarity assay was the most sensitive free-toxin immunoassay, capable of providing CDI diagnosis in a single-step solution. A different CCCNA result was reported for 42% of retested samples, increasing the positive agreement between Clarity and CCCNA from 85.2% to 96.3% and indicating the challenges of comparing free-toxin results to CCCNA results as a reference standard.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Hansen G, Young S, Wu AHB, et al. Ultrasensitive Detection of Clostridioides difficile Toxins in Stool by Use of Single-Molecule Counting Technology: Comparison with Detection of Free Toxin by Cell Culture Cytotoxicity Neutralization Assay. J Clin Microbiol. 2019. PMID: 31434724. doi:10.1128/JCM.00719-19

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。